Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.

Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J.

Curr Med Res Opin. 2007 Oct;23(10):2585-96.

PMID:
17875242
2.
3.

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.

Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP.

Clin Drug Investig. 2008;28(9):583-601.

PMID:
18666805
4.

Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico.

Carlos F, Ramírez-Gámez J, Dueñas H, Galindo-Suárez RM, Ramos E.

J Med Econ. 2012;15(2):233-44. doi: 10.3111/13696998.2011.640730. Epub 2011 Dec 5.

PMID:
22082033
5.

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.

Quilici S, Chancellor J, Löthgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B.

BMC Neurol. 2009 Feb 10;9:6. doi: 10.1186/1471-2377-9-6.

6.

A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.

Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J.

BMC Neurol. 2011 Jan 20;11:7. doi: 10.1186/1471-2377-11-7.

7.

A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.

O'Connor AB, Noyes K, Holloway RG.

J Am Geriatr Soc. 2007 Aug;55(8):1176-84. Review.

PMID:
17661955
8.
9.

Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.

Navarro A, Saldaña MT, Pérez C, Masramón X, Rejas J.

Pain Pract. 2012 Jun;12(5):382-93. doi: 10.1111/j.1533-2500.2011.00515.x. Epub 2011 Oct 18.

PMID:
22004531
10.

[Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam].

Díaz S, Argumosa A, Horga de la Parte JF, Vera-Llonch M, Dukes E, Rejas-Gutiérrez J.

Rev Neurol. 2007 Oct 16-31;45(8):460-7. Spanish.

11.

Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy.

Toth C.

Pain Med. 2010 Mar;11(3):456-65. doi: 10.1111/j.1526-4637.2009.00796.x. Epub 2010 Jan 22.

12.

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.

Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G.

Curr Med Res Opin. 2010 Apr;26(4):965-75. doi: 10.1185/03007991003600271.

PMID:
20178405
13.

A cost-utility comparison of four first-line medications in painful diabetic neuropathy.

O'Connor AB, Noyes K, Holloway RG.

Pharmacoeconomics. 2008;26(12):1045-64. doi: 10.2165/0019053-200826120-00007.

PMID:
19014205
14.

Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.

Ritchie M, Liedgens H, Nuijten M.

Clin Drug Investig. 2010;30(2):71-87. doi: 10.2165/11533310-000000000-00000.

PMID:
20067326
15.

Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study.

Happich M, Schneider E, Boess FG, Wilhelm S, Schacht A, Birklein F, Ziegler D.

Clin J Pain. 2014 Oct;30(10):875-85. doi: 10.1097/AJP.0000000000000057.

PMID:
24296910
16.
17.

A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.

de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J.

Pain Med. 2012 May;13(5):699-710. doi: 10.1111/j.1526-4637.2012.01375.x.

18.

Pregabalin: new drug. Very similar to gabapentin.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):203-6.

PMID:
16397976
19.

Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.

Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

J Pain. 2006 Jun;7(6):399-407.

PMID:
16750796
20.

5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.

Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M.

Curr Med Res Opin. 2009 Jul;25(7):1663-76. doi: 10.1185/03007990903047880.

PMID:
19485723
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk